643 related articles for article (PubMed ID: 34114161)
1. Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.
Sadeqi Nezhad M; Abdollahpour-Alitappeh M; Rezaei B; Yazdanifar M; Seifalian AM
Pharm Res; 2021 Jun; 38(6):931-945. PubMed ID: 34114161
[TBL] [Abstract][Full Text] [Related]
2. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.
Saetersmoen ML; Hammer Q; Valamehr B; Kaufman DS; Malmberg KJ
Semin Immunopathol; 2019 Jan; 41(1):59-68. PubMed ID: 30361801
[TBL] [Abstract][Full Text] [Related]
3. Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor T Cells: The Intersection of Stem Cells and Immunotherapy.
Lahimchi MR; Maroufi F; Maali A
Cell Reprogram; 2023 Oct; 25(5):195-211. PubMed ID: 37782910
[TBL] [Abstract][Full Text] [Related]
4. 3D-organoid culture supports differentiation of human CAR
Wang Z; McWilliams-Koeppen HP; Reza H; Ostberg JR; Chen W; Wang X; Huynh C; Vyas V; Chang WC; Starr R; Wagner JR; Aguilar B; Yang X; Wu X; Wang J; Chen W; Koelker-Wolfe E; Seet CS; Montel-Hagen A; Crooks GM; Forman SJ; Brown CE
Cell Stem Cell; 2022 Apr; 29(4):515-527.e8. PubMed ID: 35278370
[TBL] [Abstract][Full Text] [Related]
5. Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells for the Treatment of Hepatocellular Carcinoma: Potential and Challenges.
Lu F; Ma XJ; Jin WL; Luo Y; Li X
Front Immunol; 2021; 12():690565. PubMed ID: 34054880
[TBL] [Abstract][Full Text] [Related]
6. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
7. Advances in Adoptive Cell Therapy Using Induced Pluripotent Stem Cell-Derived T Cells.
Netsrithong R; Wattanapanitch M
Front Immunol; 2021; 12():759558. PubMed ID: 34650571
[TBL] [Abstract][Full Text] [Related]
8. Off-the-Shelf Chimeric Antigen Receptor Immune Cells from Human Pluripotent Stem Cells.
Cao H; Sugimura R
Cancer Treat Res; 2022; 183():255-274. PubMed ID: 35551663
[TBL] [Abstract][Full Text] [Related]
9. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
[TBL] [Abstract][Full Text] [Related]
10. Generating universal chimeric antigen receptor expressing cell products from induced pluripotent stem cells: beyond the autologous CAR-T cells.
Deng X; Zhou J; Cao Y
Chin Med J (Engl); 2023 Jan; 136(2):127-137. PubMed ID: 36806264
[TBL] [Abstract][Full Text] [Related]
11. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
Nguyen S; Lacan C; Roos-Weil D
Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
[TBL] [Abstract][Full Text] [Related]
12. IPSC-derived CAR-NK cells for cancer immunotherapy.
Lin X; Sun Y; Dong X; Liu Z; Sugimura R; Xie G
Biomed Pharmacother; 2023 Sep; 165():115123. PubMed ID: 37406511
[TBL] [Abstract][Full Text] [Related]
13. The making and function of CAR cells.
Zabel M; Tauber PA; Pickl WF
Immunol Lett; 2019 Aug; 212():53-69. PubMed ID: 31181279
[TBL] [Abstract][Full Text] [Related]
14. Induced Pluripotent Stem Cell (iPSC)-Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges.
Nianias A; Themeli M
Curr Hematol Malig Rep; 2019 Aug; 14(4):261-268. PubMed ID: 31243643
[TBL] [Abstract][Full Text] [Related]
15. Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma.
Harada S; Ando M; Ando J; Ishii M; Yamaguchi T; Yamazaki S; Toyota T; Ohara K; Ohtaka M; Nakanishi M; Shin C; Ota Y; Nakashima K; Ohshima K; Imai C; Nakazawa Y; Nakauchi H; Komatsu N
Mol Ther; 2022 Feb; 30(2):534-549. PubMed ID: 34628050
[TBL] [Abstract][Full Text] [Related]
16. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy.
Themeli M; Kloss CC; Ciriello G; Fedorov VD; Perna F; Gonen M; Sadelain M
Nat Biotechnol; 2013 Oct; 31(10):928-33. PubMed ID: 23934177
[TBL] [Abstract][Full Text] [Related]
17. Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring "Universal" Donor T Cells.
Perez C; Gruber I; Arber C
Front Immunol; 2020; 11():583716. PubMed ID: 33262761
[TBL] [Abstract][Full Text] [Related]
18. Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy - Moving Target for Industry?
Salmikangas P; Kinsella N; Chamberlain P
Pharm Res; 2018 May; 35(8):152. PubMed ID: 29855723
[TBL] [Abstract][Full Text] [Related]
19. Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity.
Li Y; Hermanson DL; Moriarity BS; Kaufman DS
Cell Stem Cell; 2018 Aug; 23(2):181-192.e5. PubMed ID: 30082067
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]